Therapeutic actions of cyclosporine and anti-tumor necrosis factor α in collagen-induced arthritis and the effect of combination therapy

Arthritis and Rheumatism

Volumn 41, Issue 10, 1998, Pages 1806-1812

  Williams, Richard O ^a   Mauri, Claudia ^a   Mason, Lesley J ^a   Marinova Mutafchieva, Lilia ^a   Ross, Susan E ^a   Feldmann, Marc ^a   Maini, Ravinder N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; CYCLOSPORIN; CYCLOSPORIN A; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELLULAR IMMUNITY; COLLAGEN DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HELPER CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; COLLAGEN; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; MALE; MICE; MICE, INBRED DBA; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031714119     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199810)41:10<1806::AID-ART12>3.0.CO;2-9     Document Type: Article

References (19)

1. Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-10.
2. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992;89:7375-9.
3. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
4. Van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994;95:237-43.
5. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A 1994;91: 2762-6.
6. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84:433-9.
7. Yocum DE. Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 1996;22:133-54.
8. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumour necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
9. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996;26:1511-8.
10. Sheehan KC, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989;142:3884-93.
11. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997;107:507-12.
12. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992;357:692-4.
13. Nguyen DT, Eskandai MK, DeForge LE, Raiford CL, Strieter RM, Kunkel SL, et al. Cyclosporin A modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J Immunol 1990;144:3822-8.
14. Hom JT, Butler LD, Riedl PE, Bendele AM. The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur J Immunol 1988;18: 881-8.
15. Goldschmidt TJ, Holmdahl R. Anti-T cell receptor antibody treatment of rats with established autologous collagen-induced arthritis: suppression of arthritis without reduction of anti-type II collagen autoantibody levels. Eur J Immunol 1991;21:1327-30.
16. Yoshino S, Cleland LG. Depletion of α/β T cells by a monoclonal antibody against the α/β T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats. J Exp Med 1992;175:907-15.
17. Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, et al. Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody. Arthritis Rheum 1994;37:406-13.
18. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996;26:2320-8.
19. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Low dose methotrexate suppresses antiglobulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody given repeatedly in rheumatoid arthritis [abstract]. Arthritis Rheum 1997;40 Suppl 9:S126.